Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab-Govitecan Plus Q901 in Advanced TNBC
NCT07788222Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Sep 2026
- Primary completion
- May 2028
01
Overview
Phase 2, open-label, single-arm trial of mocaciclib in triple-negative breast cancer (TNBC), sponsored by Yonsei University. Primary endpoint: Objective Response Rate at 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mocaciclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07788222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788222.